Lymphohistiocytosis Clinical Trials

12 recruitingLast updated: May 13, 2026

There are 12 actively recruiting lymphohistiocytosis clinical trials across 10 countries. Studies span Phase 2, Phase 3, Phase 1, Not Applicable, Phase 4. Top locations include Beijing, Beijing Municipality, China, Beijing, China, Birmingham, Alabama, United States. Updated daily from ClinicalTrials.gov.


Lymphohistiocytosis Trials at a Glance

12 actively recruiting trials for lymphohistiocytosis are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Beijing, Beijing, and Birmingham. Lead sponsors running lymphohistiocytosis studies include Beijing Friendship Hospital, Beijing Children's Hospital, and Assistance Publique - Hôpitaux de Paris.

Browse lymphohistiocytosis trials by phase

Treatments under study

About Lymphohistiocytosis Clinical Trials

Looking for clinical trials for Lymphohistiocytosis? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphohistiocytosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphohistiocytosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2Phase 3

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics Inc.156 enrolled40 locationsNCT05416307
Recruiting
Phase 2

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

Haemophagocytic Lymphohistiocytosis
Assistance Publique - Hôpitaux de Paris20 enrolled1 locationNCT05762640
Recruiting
Phase 1Phase 2

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Extranodal NK T Cell LymphomaHemophagocytic Lymphohistiocytosis (HLH)
Beijing Tongren Hospital25 enrolled1 locationNCT07525466
Recruiting

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Lymphohistiocytosis, HemophagocyticSecondary Hemophagocytic LymphohistiocytosisMacrophage Activation Syndrome+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled2 locationsNCT06339177
Recruiting
Not Applicable

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

EBV-associated T/NK-cell Lymphoproliferative DiseasesRefractory/Relapsed EBV-related Hemophagocytic LymphohistiocytosisLetermovir
Beijing Children's Hospital80 enrolled1 locationNCT07488728
Recruiting
Phase 2Phase 3

Golidocitinib Combined With Selinexor for CAEBVD

EBVLymphohistiocytosisCAEBV
Beijing Friendship Hospital28 enrolled1 locationNCT07369739
Recruiting
Phase 2Phase 3

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Lymphohistiocytosis, Hemophagocytic
Beijing Friendship Hospital28 enrolled1 locationNCT07339345
Recruiting
Phase 4

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

B-cell LymphomaHemophagocytic Lymphohistiocytosis
The First Affiliated Hospital of Soochow University40 enrolled1 locationNCT07270835
Recruiting
Phase 3

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.30 enrolled15 locationsNCT07208058
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting

Assessing the Presence of CT-DNA in Lymphoma Associated HLH

LymphomaHaemophagocytic Lymphohistiocytosis
Nottingham University Hospitals NHS Trust12 enrolled1 locationNCT05702502
Recruiting
Phase 1

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

EBV InfectionEBV-associated Hemophagocytic Lymphohistiocytosis
Chinese PLA General Hospital9 enrolled1 locationNCT06135922